Standout Papers

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial 2002 2026 2010 2018 3.1k
  1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (2002)
    Stephen B. Hanauer, Brian G. Feagan et al. The Lancet
  2. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial (2006)
    Jean–Frédéric Colombel, William J. Sandborn et al. Gastroenterology
  3. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017)
    William J. Sandborn, Chinyu Su et al. New England Journal of Medicine
  4. XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel Disease (2008)
    Arthur Kaser, Ann–Hwee Lee et al. Cell
  5. Mucosal flora in inflammatory bowel disease (2002)
    Alexander Swidsinski, Axel Ladhoff et al. Gastroenterology
  6. Certolizumab Pegol for the Treatment of Crohn's Disease (2007)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  7. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations (2001)
    Jochen Hampe, Andrew Cuthbert et al. The Lancet
  8. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
    William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine
  9. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease (2007)
    Stefan Schreiber, Ian C. Lawrance et al. New England Journal of Medicine
  10. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease (2004)
    Paul Rutgeerts, Brian G. Feagan et al. Gastroenterology
  11. Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease (1993)
    Martín Steffen, T. Witthoeft et al. Clinical & Experimental Immunology
  12. Natalizumab Induction and Maintenance Therapy for Crohn's Disease (2005)
    William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine
  13. Activation of nuclear factor κB in inflammatory bowel disease (1998)
    Stefan Schreiber, Susanna Nikolaus et al. Gut
  14. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease (2002)
    Andrew Cuthbert, Sheila Fisher et al. Gastroenterology
  15. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection (2016)
    S. Ott, Georg H. Waetzig et al. Gastroenterology
  16. Twin Study Indicates Loss of Interaction Between Microbiota and Mucosa of Patients With Ulcerative Colitis (2011)
    Patricia Lepage, Robert Häsler et al. Gastroenterology
  17. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer (2013)
    Aurélie Couturier-Maillard, Thomas Sécher et al. Journal of Clinical Investigation
  18. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (2019)
    Bruce E. Sands, Laurent Peyrin‐Biroulet et al. New England Journal of Medicine
  19. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases (2017)
    Susanna Nikolaus, Berenice Schulte et al. Gastroenterology
  20. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial (2016)
    Séverine Vermeire, Stefan Schreiber et al. The Lancet
  21. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017)
    Julián Panés, William J. Sandborn et al. Gut
  22. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis (2020)
    William J. Sandborn, Subrata Ghosh et al. Gastroenterology
  23. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
    William J. Sandborn, Séverine Vermeire et al. The Lancet

Immediate Impact

8 by Nobel laureates 47 from Science/Nature 239 standout
Sub-graph 1 of 15

Citing Papers

Immune regulation by fungal strain diversity in inflammatory bowel disease
2022 StandoutNature
Host–microbiota maladaptation in colorectal cancer
2020 StandoutNature
139 intermediate papers

Works of Stefan Schreiber being referenced

NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer
2013 Standout
Association between intraepithelial Escherichia coli and colorectal cancer
1998
and 79 more

Author Peers

Author Last Decade Papers Cites
Stefan Schreiber 25944 17883 13442 870 50.1k
Séverine Vermeire 34605 25404 13971 1.2k 53.6k
Silvio Danese 28863 20178 12002 1.3k 48.6k
Jean‐Frédéric Colombel 41043 31226 12563 711 57.3k
Laurent Peyrin‐Biroulet 32828 24374 9612 1.1k 47.8k
Markus F. Neurath 16206 9101 21948 902 55.3k
Bruce E. Sands 27560 20316 9724 579 38.2k
Çharles N. Bernstein 17665 14165 3994 721 39.4k
Paul Rutgeerts 47645 36937 17665 554 63.7k
Remo Panaccione 25603 18908 8003 684 35.4k
Warren Strober 10858 7855 26036 430 48.8k

All Works

Loading papers...

Rankless by CCL
2026